Evaluating marker-guided treatment selection strategies

Biometrics

Volumn 70, Issue 3, 2014, Pages 489-499

  Matsouaka, Roland A ^a   Li, Junlong ^a   Cai, Tianxi ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomarker analysis design; Counterfactual outcome; Personalized medicine; Perturbation resampling; Predictive biomarkers; Subgroup analysis

Indexed keywords

PATIENT TREATMENT;

ANALYSIS/DESIGN; BIOMARKER-ANALYSE DESIGN; COUNTERFACTUAL OUTCOME; COUNTERFACTUALS; PERSONALIZED MEDICINES; PERTURBATION-RESAMPLING; PREDICTIVE BIOMARKER; RESAMPLING; SUBGROUP ANALYSE; TREATMENT SELECTION;

BIOMARKERS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; CD4 ANTIGEN; DRUG COMBINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD; CONTROLLED STUDY; DRUG COMBINATION; HUMAN; OUTCOME ASSESSMENT; PREVALENCE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIGENS, CD4; BIOMARKERS; DATA INTERPRETATION, STATISTICAL; DRUG COMBINATIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84927697541     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/biom.12179     Document Type: Article

References (29)

1. Baker, S., Kramer, B., Sargent, D., and Bonetti, M. (2012). Biomarkers, subgroup evaluation, and clinical trial design. Discovery Medicine 13, 187-192.
2. Bonetti, M. and Gelber, R. (2000). A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Statistics in Medicine 19, 2595-2609.
3. Bonetti, M. and Gelber, R. (2004). Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5, 465-481.
4. Cai, T., Tian, L., and Wei, L. (2005). Semiparametric Box-Cox power transformation models for censored survival observations. Biometrika 92, 619-632.
5. Cai, T., Tian, L., Wong, P., and Wei, L. (2011). Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12, 270-282.
6. Foster, J., Taylor, J., and Ruberg, S. (2011). Subgroup identification from randomized clinical trial data. Statistics in Medicine 30, 2867-2880.
7. Hammer, S., Squires, K., Hughes, M., Grimes, J., Demeter, L., Currier, J., Eron, J., Feinberg, J., Balfour, H., Deyton, L., Chodakewitz, J., and Fischl, M. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 337, 725-733.
8. Holland, P. W. (1986). Statistics and causal inference. Journal of the American statistical Association 81, 945-960.
9. Huang, Y., Gilbert, P. B., and Janes, H. (2012). Assessing treatment-selection markers using a potential outcomes framework. Biometrics 68, 687-696.
10. Hughes, M. D., Stein, D. S., Gundacker, H. M., Valentine, F. T., Phair, J. P., and Volberding, P. A. (1994). Within-subject variation in cd4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. Journal of Infectious Diseases 169, 28-36.
11. Imai, K. and Strauss, A. (2011). Estimation of heterogeneous treatment effects from randomized experiments, with application to the optimal planning of the get-out-the-vote campaign. Political Analysis 19, 1-19.
12. Janes, H., Pepe, M., Bossuyt, P., and Barlow, W. (2011). Measuring the performance of markers for guiding treatment decisions. Annals of Internal Medicine 154, 253-259.
13. Kent, D. M. and Hayward, R. A. (2007). Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. Journal of American Medical Association 298, 1209-1212.
14. Kim, J. and Pollard, D. (1990). Cube root asymptotics. The Annals of Statistics 18, 191-219.
15. Park, Y. and Wei, L. (2003). Estimating subject-specific survival functions under the accelerated failure time model. Biometrika 90, 717-723.
16. Qian, M. and Murphy, S. (2011). Performance guarantees for individualized treatment rules. Annals of Statistics 39, 1180-1210.
17. Robins, J. (1986). A new approach to causal inference in mortality studies with a sustained exposure period-Application to control of the healthy worker survivor effect. Mathematical Modelling 7, 1393-1512.
18. Rothwell, P. (1995). Can overall results of clinical trials be applied to all patients? The Lancet 345, 1616-1619.
19. Rothwell, P., Mehta, Z., Howard, S., Gutnikov, S., and Warlow, C. (2005). From subgroups to individuals: general principles and the example of carotid endarterectomy. The Lancet 365, 256-265.
20. Rubin, D. (1980). Randomization analysis of experimental data: The fisher randomization test comment. Journal of the American Statistical Association 75, 591-593.
21. Rubin, D. (1986). Statistics and causal inference: Comment: Which ifs have causal answers. Journal of the American Statistical Association 81, 961-962.
22. Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of educational Psychology 66, 688.
23. Rubin, D. B. (1978). Bayesian inference for causal effects: The role of randomization. The Annals of Statistics 6, 34-58.
24. Song, X. and Pepe, M. (2004). Evaluating markers for selecting a patient's treatment. Biometrics 60, 874-883.
25. Song, X. and Zhou, X.-H. (2009). Evaluating markers for treatment selection based on survival time. UW Biostatistics Working Paper Series Working Paper 349: 1-27.
26. Zhang, B., Tsiatis, A. A., Davidian, M., Zhang, M., and Laber, E. (2012a). Estimating optimal treatment regimes from a classification perspective. Stat 1, 103-114.
27. Zhang, B., Tsiatis, A. A., Laber, E. B., and Davidian, M. (2012b). A robust method for estimating optimal treatment regimes. Biometrics 68, 1010-1018.
28. Zhao, L., Tian, L., Cai, T., Claggett, B., and Wei, L. (2013). Effectively selecting a target population for a future comparative study. Journal of the American Statistical Association 108, 527-539.
29. Zhao, Y., Zeng, D., Rush, A., and Kosorok, M. (2012). Estimating individualized treatment rules using outcome weighted learning. Journal of the American Statistical Association 107, 1106-1118.